Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XG004 in osteoarthritis of the knee
NCT05454020Phase 1Completed
- Sponsor
- Xgene Pharmaceutical Inc.
- Start
- Jun 2022
- Primary completion
- Jan 2023
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in knee osteoarthritis (OA) comparing A (XG004) with B (Placebo) (2 arms). Primary endpoint: Incidence of Treatment Emergent Adverse Events. Started Jun 2022; status: completed.
02
Drugs
naproxen/pregabalin conjugate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05454020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05454020.